J C E M O N L I N E
H o t T o p i c s i n T r a n s l a t i o n a l E n d o c r i n o l o g y — E n d o c r i n e C a r e
Calcium and Vitamin D Supplementation in
Postmenopausal Women
John F. Aloia, Ruban Dhaliwal, Albert Shieh, Mageda Mikhail, Shahidul Islam,
and James K. Yeh
WinthropUniversityHospital,BoneMineralResearchCenter,Mineola,NewYork11501
Context:BonehealthisinfluencedbytheintakeofbothcalciumandvitaminD.
Objective:OurobjectivewastoevaluatetheinfluenceofcalciumandvitaminDsupplementation
onPTHandboneturnover.
Setting, Patients, and Design: At an ambulatory research center, 159 postmenopausal healthy
whitewomenparticipatedinthisdouble-blind,placebo-controlledparallel,longitudinalfactorial
studythatwas6monthsinduration.
Interventions:Subjectswererandomlyallocatedto4groups:1)doubleplacebo,2)calcium(1200
mgdaily)plusplacebo,3)vitaminD (100(cid:1)g)plusplacebo,and4)vitaminD andcalcium.Serum
3 3
andurinewerecollectedfastingand2hoursafteracalciumloadatbaselineandat3and6months.
MainOutcomeMeasures:SerumPTH,cross-linkedC-telopeptide(CTX),andprocollagentypeI
N-terminalpropeptide(P1NP)weremeasured.
Results:Beforestudymedication,acalciumloadresultedinadeclineinPTHandCTXandanincrease
inurinarycalciumexcretion.SerumCTXandP1NPdeclinedovertimewithcalciumsupplementation
butdidnotchangewithincreasedvitaminDintake.TherewasadeclineinPTHinthevitaminDgroups
inthefastingstatecomparedwithplacebo.SuppressionofPTHwasgreaterafteracalciumloadinthe
vitaminDgroups.AcalciumloaddecreasedPTHandCTXandraisedurinarycalcium.
Conclusions: Fasting PTH declines with vitamin D supplementation. PTH declines after calcium
intake. Supplementation of the diet with 1200 mg calcium/d reduces bone turnover markers,
whereassupplementationwithupto100(cid:1)gvitaminD /ddoesnot.(JClinEndocrinolMetab98:
3
E1702–E1709,2013)
The recent Institute of Medicine (IOM) report on di- RDAand10,000IUfortheUL)(4).Bothconclusionswere
etary reference intakes for calcium and vitamin D basedontheindicatorbonehealth,acompositeoffactors
recommended a calcium intake of 1200 mg/d for those includingfractureprevention,boneloss,andosteomala-
over50yearsoldwithatolerableupperlimit(UL)of2000 cia.OthernonskeletalindicatorsofvitaminDsufficiency
mg/d(1–3).VitaminDintakeof600IU/dfromage50to havebeenproposed,butneithertheIOMnortheEndo-
70,and800IU/dover71yearsfortherecommendeddaily crineSocietyfoundsufficientevidencethatinformedthe
allowance (RDA) with an upper limit of 4000 IU/d was formulationofanRDAforvitaminDusingtheseputative
recommended.Thesedietaryreferenceintakeshavebeen biomarkers(1,2,4,5).
challengedinanEndocrineSocietyClinicalGuidelinethat Clinicaltrialsoffracturepreventionconfirmabenefi-
implied that vitamin D intake should be substantially cialeffectofcalciumwithvitaminDsupplementationin
higherinmuchofthepopulation(1500–2000IUforthe combination (6). However, it is difficult to discern the
ISSNPrint0021-972X ISSNOnline1945-7197 Abbreviations:Ca/Cr,calcium/creatinine;CTX,cross-linkedC-telopeptide;1,25(OH)D,
2
PrintedinU.S.A. 1,25-dihydroxyvitaminD;25(OH)D,25-hydroxyvitaminD;P1NP,procollagentypeIN-ter-
Copyright©2013byTheEndocrineSociety minalpropeptide;RDA,recommendeddailyallowance;UL,upperlimit.
ReceivedMay1,2013.AcceptedAugust28,2013.
FirstPublishedOnlineSeptember24,2013
E1702 jcem.endojournals.org JClinEndocrinolMetab,November2013,98(11):E1702–E1709 doi:10.1210/jc.2013-2121
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
doi:10.1210/jc.2013-2121 jcem.endojournals.org E1703
separate contributions of these nutrients. In a previous cludedanychronicmedicalillness,osteoporosis,pregnancy,use
study, we examined the influence of calcium intake and ofmedicationsthatinfluencebonemetabolismorinterferewith
vitaminDmetabolism,andunexplainedweightlossduringthe
vitamin D separately as well as their interaction on bio-
previousyear.Participantsagreedtorefrainfromincreasingdi-
markersofskeletalnutritionalsufficiency,ie,serumPTH
etarycalciumintakeorfromtakingself-prescribedcalciumor
andboneturnovermarkers(7).BecausevitaminDenables vitaminDsupplementsduringthestudy.
calcium absorption, studies were also performed after a ThestudywasapprovedbytheInstitutionalReviewBoardof
calciumloadtoexaminetheinfluenceofcalciumandvi- WinthropUniversityHospital.Allparticipantsgavewrittencon-
sentbeforeparticipationinanystudy-relatedactivity.Allpar-
taminDsupplementationinthepostabsorptivestate.Cal-
ticipantsandinvestigatorswereblindedtoallocationthrough-
ciumsupplementationwasfoundtolowerboneturnover
out the study except for the research pharmacist and the
markers, but supplementation with 4000 IU vitamin D
statisticalgroup.Atotalof159subjectsqualifiedandconsented
dailyhadnoeffectonboneturnoverorPTHlevels. tothestudy.
Several weaknesses in this previous study were recog- Subjectshadabaselinescreeningvisitfollowedbyaninitial
nized.Thestudypopulationwasnotuniformingender,eth- randomization visit and then visits 15 and 28 weeks later. A
completemedicalhistoryandphysicalexaminationwasdone.A
nicity,orage,andthestudydurationwasonly3months.As
3-daydietaryquestionnairewasfilledoutbyparticipantstoas-
aresultoftheselimitations,wedecidedtorepeatthisstudy
sessdailycalciumandvitaminDintake.Bodyweightandheight
in a more uniform population of postmenopausal white (usingaHarpendenstadiometer)wererecorded.Baselinefasting
womenwithalargersamplesizeandgreaterstudyduration. laboratorytestsincludedserumcalcium,phosphorus,serum25-
Ourgoalwastoreexaminetheinfluenceofcalciumand/or hydroxyvitaminD(25(OH)D),serum1,25-dihydroxyvitaminD
(1,25(OH) D), serum PTH, serum cross-linked C-telopeptide
vitaminDsupplementationonboneturnoverandPTHlevels 2
(CTX),serumprocollagentypeIN-terminalpropeptide(P1NP),
inthefastingandpostprandialstates.
and fasting urine calcium and creatinine (8, 9). After collecting
fastingbloodandurinesamples,participantsweregivena600-mg
calciumtabletintheformofcalciumcarbonatewithalightbreak-
Subjects and Methods fasttoeat.Breakfastconsistedofteaorcoffeewithasmallamount
ofmilkandtwoslicesofwhitebread(40mgofcalciumperslice)
Atotalof363healthypostmenopausalwhiteparticipantswere withbutter.Twohoursaftertheoralcalciumload,serumcalcium,
recruitedfromWinthropUniversityHospitalanditssurround- 1,25(OH) D,PTH,CTX,andP1NPandurinecalcium/creatinine
2
ingarea(Figure1).ParticipationinthistrialbeganinDecember (Ca/Cr)wereagainmeasured.Thefastingandcalciumloadstudies
2008 and ended in April 2011. Recruitment was carried out describedabovewererepeatedateachvisit.
during winter in consecutive years through e-mail, advertise- Atthesecondbaselinevisit,159participantswhoqualifiedforthe
mentsinthelocalpaper,andadirectmailcampaign.Subjects studywereassignedto1of4groupsbyasimplerandomization:1)
wereenrolledintwoconsecutivewinters.Exclusioncriteriain- placebovitaminD supplementandactivecalciumsupplement,2)
3
activevitaminD supplementandplacebo
3
calciumsupplement,3)bothactivevitamin
D andactivecalciumsupplements,and4)
3
bothplacebovitaminD andplacebocal-
3
cium supplements. All subjects took one
600-mgtabletofcalcium(orplacebo)inthe
morning and in the evening for a dose of
1200mgdaily(ornocalcium).VitaminD
3
supplements were administered in 50-(cid:1)g
capsules.Allsubjectstookonedoseofvita-
minD (orplacebo)inthemorningandone
3
intheeveningforadoseof100(cid:1)g(4000IU)
daily(ornovitaminD).Inthisdouble-blind,
placebo-controlled,parallel-group,longitu-
dinalfactorialdesign,patientsandresearch-
erswereblindedtogroupassignment.The
trial was recorded with www.Clinical
Trials.gov at http://clinicaltrials.gov/ct2/
show/NCT00762775?term_nct0076775&
rank_1.
Medications were provided in vials
containing enough doses for 12 weeks.
Theactiveandplacebocalciumsupple-
mentsandtheactiveandplacebovitamin
Dsupplementshadidenticalappearance
and weights. The compositions of the
Figure1. Flowchartofthestudy. placeboswereinertmaterials.Anycon-
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
E1704 Aloiaetal CalciumandVitaminDSupplementation JClinEndocrinolMetab,November2013,98(11):E1702–E1709
Table 1. BaselineCharacteristicsa
RandomizationGroup
Variable VitaminD CalciumandVitaminD Calcium Placebo
Age,y 59.7(7.1) 57.6(7.1) 60(8.)5 58.6(6.7)
BMI,kg/m2 26.9(3.6) 27.4(3.9) 26.7(3.3) 26.8(3.9)
DietaryvitaminD,IU/d 180(163) 158(105) 185(140) 215(205)
DietaryCa,mg/d 876(310) 907(288) 906(320) 890(259)
PTH,pg/mL 37.4(16) 33.5(13) 39.1(17) 35.7(15)
P1NP,(cid:1)g/L 55.8(21) 52.5(18) 53.8(21) 56.3(21)
CTX,ng/mL 0.53(0.21) 0.47(0.17) 0.54(0.25) 0.51(0.21)
1,25D,pmol/L 113(42) 108(37) 115(29) 113(34)
25(OH)D,nmol/L 64(16) 69(17) 66(19) 67(17)
UrinaryCa/Cr 0.11(0.07) 0.12(0.06) 0.10(0.07) 0.11(0.07)
aReferencelaboratoryrangesareasfollows:PTH,17–72pg/mL;P1NP,16–96(cid:1)g/L;CTX,0.142–1.351ng/mL;1,25(OH) D,39–193pmol/L;
2
25(OH)D,50–125nmol/L;urinaryCa/Cr,(cid:1)0.37.
comitant medications or adverse events were recorded. At atinine. Participants were given a 600-mg calcium tablet (cal-
4-weekintervals,subjectswerecontactedtoencouragecompli- ciumcarbonate)againaccompaniedbyalightbreakfast.After2
ance and record any adverse events. Participants returned for hours,postprandialbloodandurinesampleswerecollected.All
visitsafter15and28weeks.The3-daydietaryrecordwascol- unusedstudymedicationwascollectedandcountedtoevaluate
lectedalongwiththeremainingpills.Apillcountwasdoneasa forcompliance.VitaminD capsuleswerecustommanufactured
3
meansofmeasuringcompliance.Vitalsigns,height,weight,and byTishconCorp,andtheircontentwasverifiedinanindepen-
travelhistorywerecollected.Anyconcomitantmedicationsand dentlaboratory(VitaminD,Skin,andBoneResearchLabora-
adverse events were recorded. Fasting serum calcium, serum tory,DepartmentofMedicine,BostonUniversitySchoolofMed-
25(OH)D,serumPTH,serumCTX,andserumP1NPwerecol- icine,Boston,Massachusetts).
lected.Fastingurinesampleswereanalyzedforcalciumandcre-
Biochemistry
Serum25(OH)Dwasmeasuredbyan
RIA from DiaSorin, Inc. The minimum
andmaximumdetectablelevelsare3.75
and250nmol/L,respectively.Theintra-
assayprecision(coefficientofvariation)
for the mean of 21.5 nmol/L is 11.7%
and for the mean of 122.5 nmol/L is
12.5%.Theoverallintra-assayvariabil-
ityinourlaboratoryis4.1%,andinter-
assayvariabilityis7.0%.Ourlaboratory
participatesinandhasbeencertifiedcon-
tinuously since 2005 by the Vitamin D
ExternalQualityAssessmentScheme,an
external quality control program (10).
Thereferencerangeforserum25(OH)D
is50to125nmol/L.Serumandurinary
calcium were measured by O-cresol-
phthalein complex using automated
equipmentDimension-RXL(DadeBeh-
ring). Urinary creatinine was measured
byJaffereactionwithautomatedinstru-
mentationDimension-RXL.SerumPTH
wasmeasuredbytheImmulite2000an-
alyzerforthequantitativemeasurement
of intact PTH (Diagnostic Products
Corp).SerumCTXwasmeasuredbythe
Serum Crosslaps ELISA kit made by
Nordic Bioscience Diagnostics. Serum
P1NP was measured using the UniQ
P1NPRIAkitfromOrionDiagnostica.
Figure2. A–D,Responsetoacalciumloadbeforeinterventionin159subjectsforPTH(A),urine SerumCTXprovidesameasureofbone
Ca/Cr(B),CTX(C),andP1NP(D).ReportedPvaluesareforcomparisonbetweenfastingand resorption,andP1NPisamarkeroftype
calciumload. Icollagensynthesis.Serum1,25(OH) D
2
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
doi:10.1210/jc.2013-2121 jcem.endojournals.org E1705
concentrationsweremeasuredbyanELISAkitmadebyImmu- Therewerenosignificantgroupdifferencesindietarycal-
nodiagnostic Systems. The inter- and intra-assay variability in ciumthroughoutthisstudy.
our laboratory is 17% and 10%, respectively, The reference
The distribution of baseline fasting PTH was as fol-
rangeforthisassayis39to193pmol/L.
lows: (cid:2)65 pg/mL, n (cid:3) 6. The baseline 25(OH)D distri-
Nutrition assessment
butionwasasfollows:(cid:1)50nmol/L,n(cid:3)35;(cid:2)50nmol/L
TotaldailycalciumandvitaminDintakewasestimatedfrom
andlessthan75nmol/L,n(cid:3)73.Foursubjectshadserum
a3-daydiethistoryusingNutritionPronutritionanalysissoft- 25(OH)D(cid:1)50nmol/LandPTH(cid:2)65pg/mL.Serumfast-
ware(11). ingCTXandP1NPwereabovethereferencerangein24
and17participants,respectively.
Statistical methodology
A total of 363 women were screened, and 159 were
Thestudyconsistedof159subjectsatbaselinewithobser-
enrolled.Finalanalysesweredoneon159subjects.
vationscollectedat3timepoints(baselineand15and28weeks).
Simplerandomizationwasperformedatbaselineusingacom-
puter-generatedrandomizationlist,andsubjectswereassigned Influence2hoursafteracalciumloadbefore
to1ofthe4groups,namelyplacebo,vitaminDalone,calcium intervention(n(cid:1)159)
alone,andvitaminDpluscalcium.Allenrollmentsoccurredin
Theinfluenceofthecalciumloadperformedonallsub-
winter.Thenumberofsubjectsvariedateachtimepointdueto
jects(n(cid:3)159)beforeinterventionmaybeseeninFigure
dropouts.Atotalof120subjectscompletedthestudy.
Descriptivestatisticsarereportedasmean(SD).Arepeated- 2.Therewasnochangeinserumcreatinineor25(OH)D,
measuresmixed-effectmodel(SASProcGLIMMIX)wasused asexpected.Serumcalciumincreasedslightly(P(cid:1).0001)
forallprimaryanalysiswheretime,calcium,andvitaminDwere accompanied by a decline in serum PTH (P (cid:1) .0001).
takenasfixedeffects.Themixed-effectmodelundertheassump-
Serum CTX and P1NP declined significantly, and there
tionofignorability(12)allowedustoincludeallsubjectseven
wasasignificantincreaseinurinecalcium.
withthemissingdataatanytimepoint,thuskeepingintactthe
intent-to-treatprinciple.Weconsideredboth2-wayand3-way
interactiontermsbetweentime,calcium,andvitaminD.Asub- Values after intervention assignment in the 4
ject-specificrandomslopewasalsoincludedinthemodel,and groups in the fasting state
unstructuredvariance-covariancematrixwasusedthroughout.
DataarepresentedinTable2.Therewerenosignificant
Ineachanalysis,wewereinterestedtofindthesignificanceofthe
interactionterms(time(cid:4)vitaminDandtime(cid:4)calcium)
interactiontermbetweencalciumandvitaminDwithtime.A
posthocpoweranalysisrevealedthatourbaselinesamplesize inthefastingstateforserumcreatinineorcalciumandfor
was large enough to detect this 2-way fixed-effect interaction urineCa/Cr.Therewasasignificantdeclineinboneturn-
withsufficientpower((cid:2)80%)butwasnotsufficient((cid:1)80%)to over markers for calcium supplementation: P1NP (P (cid:1)
detecta3-wayinteractionbetweentime,calcium,andvitaminD. .002) and CTX (P (cid:1) .001), but no interaction was ob-
Consistentwiththepreviousstudybyourgroup(7),wecalcu-
servedforthevitaminDinterventions.Findingsweresim-
latedthispowerforamoderateeffectsizeasdescribedinCohen
(13).Thesignificanceofeachterm(interactionandmaineffects) ilarwhenbaselinePTHortheboneturnovermarkerswere
isreportedviaatraditionalFtestobtainedfromamixed-effect used as covariates. There was a significant decline (P (cid:1)
ANOVAusingSASsoftwareversion9.2.Atwo-tailedPvalue(cid:1)
.03) in serum 1,25(OH) D for the calcium but not the
.05wasusedtodeterminesignificance,and(cid:2)(type-1error)was 2
vitaminDintervention.
keptfixedat0.05.NostatisticalcorrectionofPvalueisreported
FastingserumPTHtrendeddownwardforthevitamin
formultiplecomparisonsbecausethishasaninflationaryeffect
on the P value (11). Hence, finding a P value close to a .05
Dintervention(P(cid:3).075)andforthecalciumintervention
thresholdshouldbetakenasexploratoryinnatureandrequires (P(cid:3).096).ThevariabilityinthefastingserumPTHvalues
confirmationwithalargerstudy.
was notable. Because of the significant correlation be-
tween baseline and subsequent values of PTH, baseline
adjustedanalysisofPTHwasperformed(Figure3).Inthis
Results
analysis,therewasasignificantdeclineinPTHovertime
Demographics ascapturedbytheinteractionbetweentimeandvitaminD
Therewerenosignificantdifferencesbetweenthestudy (F 1,113(cid:3)4.07,P(cid:3).046)andanonsignificantdeclinein
groupsinage,BMI,ordietaryintakeofcalcium(Table1). thecalcium(F 1,113(cid:3)2.26,P(cid:3).13)groups.Theslopeof
Therewerealsonosignificantdifferencesinbaselinelab- changeofPTHovertimewassignificantforthecombined
oratory values. Mean dietary calcium intake was less
treatmentgroup(P(cid:1).0003).AseparateanalysisofPTH
thantherecommendedintakeoftheIOM,andmeanse- wasalsodonecomparingindividualgroupswithplacebo
rum 25(OH)D was above the RDA-associated serum alone.ThereweresignificantdifferencesinthevitaminD
25(OH)Dconcentrationof50nmol/LbutbelowTheEn- (P(cid:1).05)andcombinedgroups(P(cid:3).02)andatrendwith
docrineSociety’srecommendedvalueof70to80nmol/L. thecalciumgroup(P(cid:3).07).
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
E1706 Aloiaetal CalciumandVitaminDSupplementation JClinEndocrinolMetab,November2013,98(11):E1702–E1709
Table 2. FastingandCalciumLoadValuesWithTreatmentAssignmentsa
UrineCa/Cr SerumCa,mg/dL 1,25(OH) D,pmol/L
2
Group Fasting Load Change Fasting Load Change Fasting Load Change
Placebo
Base 0.11(0.07) 0.17(0.09) 0.06(0.08) 9.6(0.37) 9.9(0.48) 0.28(0.3) 113.1(34.2) 111.9(36.9) (cid:5)1.14(19.7)
15wk 0.09(0.05) 0.15(0.08) 0.07(0.06) 9.6(0.41) 9.8(0.31) 0.19(0.28) 117.7(42.3) 113.5(34.7) (cid:5)2.5(24.2)
28wk 0.12(0.1) 0.22(0.26) 0.1(0.2) 9.4(0.29) 9.6(0.46) 0.2(0.33) 108.5(33.2) 112.2(32.9) 2.6(22.3)
Calcium
Base 0.1(0.07) 0.17(0.09) 0.07(0.07) 9.5(0.39) 9.7(0.43) 0.21(0.26) 115.1(28.9) 119.5(31.7) 4.47(19.6)
15wk 0.09(0.05) 0.19(0.1) 0.09(0.1) 9.5(0.44) 9.8(0.44) 0.33(0.33) 108.7(29) 108.9(34) 0.29(20.1)
28wk 0.12(0.09) 0.21(0.12) 0.1(0.08) 9.4(0.45) 9.7(0.53) 0.22(0.32) 108.3(39.8) 102(33.9) (cid:5)6.3(26.7)
VitaminD
Base 0.11(0.07) 0.16(0.09) 0.05(0.08) 9.7(0.32) 9.9(0.37) 0.22(0.3) 112.9(42.2) 116.5(45) 4.4(24.5)
15wk 0.1(0.09) 0.16(0.11) 0.05(0.08) 9.6(0.39) 9.9(0.46) 0.27(0.24) 128.9(38.5) 141.8(46.2) 11.4(39.4)
28wk 0.08(0.05) 0.18(0.1) 0.09(0.07) 9.5(0.33) 9.8(0.38) 0.28(0.3) 126.9(41) 133.3(43.8) 5.9(28.3)
Calcium(cid:6)vitaminD
Base 0.12(0.06) 0.21(0.11) 0.1(0.1) 9.6(0.41) 9.9(0.38) 0.34(0.28) 107.6(36.8) 112.7(33) 5.1(20.7)
15wk 0.14(0.09) 0.24(0.15) 0.11(0.11) 9.7(0.33) 9.9(0.38) 0.25(0.23) 100.5(25.9) 105.8(27.8) 5.3(21)
28wk 0.13(0.07) 0.27(0.15) 0.14(0.12) 9.6(0.32) 9.9(0.35) 0.23(0.24) 96.1(30.3) 102.2(36.4) 6.2(20.1)
Pvalues .671,b.08c .329,b.127c .533,b.898c .374,b.084c .372,b.164c .943,b.873c .306,b.03c 0.067,b(cid:1).001c .361,b.082c
aResultsareshownasmean(SD).Referencelaboratoryrangesareasfollows:urineCa/Cr,(cid:1)0.37;serumCa,9.1–10.4mg/dL;1,25(OH) D,
2
39–193pmol/L;P1NP,16–96(cid:1)g/L;CTX,0.142–1.351ng/mL;PTH,14–72pg/mL.Pvaluesreportedareforsecond-orderinteractionterms.
bPvaluesfortime(cid:4)vitaminDinteractioneffect.
cPvaluesfortime(cid:4)calciuminteractioneffect.
Values after intervention in the 4 groups after a website at http://jcem.endojournals.org). The dose re-
calcium load sponseiscurvilinear.Inthefastingstate,thecalciumin-
Response to the oral calcium load for each relevant take group experienced a significant decline in calcitriol
parameter is also given in Table 2. Again, as expected, overtime(F (cid:3)4.74,P(cid:3).03).Asimilarresponsewas
1,259
therewasnochangeinfastingcreatinineorserumcalcium. seen in the calcium-loaded state, with an even lower P
Calciuminterventionresultedindeclinesafteringestionof value(F (cid:3)11.26,P(cid:1).001),suggestingalargereffect
1,260
acalciumloadforPTH,(P(cid:1).038),P1NP(P(cid:1).002),and
size. Serum calcitriol in the vitamin D treatment group
CTX (P (cid:1) .003). Serum PTH declined from the fasting
showedatrendtowardincrease(SupplementalFigure2).
levels in the vitamin D intervention (P (cid:3) .038). During
supplementation,thedeclineinPTHafteracalciumload Compliance and adverse events
washigherinbothvitaminDtreatmentgroups(forcom-
Compliance (pill count) was 78% for vitamin D and
binedP(cid:3).03).Theplaceboandcalcium-alonegroupsdid
78%forcalcium.Therewerenodifferencesincompliance
notdiffersignificantlyfromthefastingresults.
foranygroup.Therewerenoseriousadverseeventsinthe
study.ReportedadverseeventsaregiveninTable3using
Response of vitamin D metabolites
aschemesimilartoMedDRA.Thepatientswhodropped
Theresponseofserum25(OH)DinthevitaminD-sup-
out because of adverse events were as follows: placebo
plemented groups is depicted in Supplemental Figure 1
group,1forflankpain;vitaminDgroup,1forasprained
(published on The Endocrine Society’s Journals Online
ankleand1forarthralgia;calciumplusvitaminDgroup,
1forconstipation,1forupsetstomach,1forpalpitations
and headaches; and calcium group, 1 for upset stomach
and 1 for leg cramps and weakness. No change in mean
serumcalciumorphosphatewasseeninthefastingstate.
Oneincidentoftransienthypercalcemiawasnotedinthe
calciumplusvitaminDgroup.
Using0.23fortheupperlimitfortheurineCa/Crratio
in the fasting state during the intervention periods, the
frequency of values exceeding this concentration was
Figure3. Groupwisemeanplotof4groupsforresponse highest in the combined treatment group (10 instances,
tofastingPTHafterbaselineadjustment.Amixed-effectsmodel compared with 1–2 in the other groups). Using the less
revealedthattheinteractiontermtime(cid:4)vitaminDwassignificant
sensitive value for defining hypercalciuria of a Ca/Cr
(F (cid:3)4.07,P(cid:3).046),andtime(cid:4)calciumwasnonsignificant
1,113
(F (cid:3)2.26,P(cid:3).13). greater than 0.37, there was only 1 episode of hypercal-
1,113
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
doi:10.1210/jc.2013-2121 jcem.endojournals.org E1707
Table 2. Continued
P1NP,(cid:2)g/L CTX,ng/mL PTH,pg/mL
Group Fasting Load Change Fasting Load Change Fasting Load Change
Placebo
Base 56.3(21.1) 54.3(22) (cid:5)1.5(9.1) 0.51(0.21) 0.31(0.12) (cid:5)0.2(0.13) 35.7(15.1) 26.9(14.9) 8.8(9.20)
15wk 56.1(19.7) 53.9(19.9) (cid:5)2.7(8.2) 0.55(0.23) 0.34(0.14) (cid:5)0.23(0.15) 35.9(14.2) 25.8(13.1) (cid:5)6.7(9.7)
28wk 55.5(22.3) 53.4(21.8) (cid:5)2.6(7.3) 0.57(0.24) 0.35(0.12) (cid:5)0.22(0.14) 36.7(18.8) 30.5(18.9) (cid:5)5.9(13.5)
Calcium
Base 53.7(21.3) 54.5(23.2) 0.35(6.5) 0.54(0.25) 0.34(0.15) (cid:5)0.23(0.16) 39.1(16.9) 26.3(12.3) (cid:5)12.8(10.1)
15wk 46.3(22.2) 48.9(25.1) (cid:5)0.16(6) 0.44(0.22) 0.29(0.16) (cid:5)0.17(0.1) 31.7(14) 25(11) 7.8(7.5)
28wk 45.1(22.9) 42.9(17.8) (cid:5)2.2(9.8) 0.5(0.27) 0.31(0.15) (cid:5)0.19(0.15) 32.9(17.1) 23.7(14.7) (cid:5)9.2(11.8)
VitaminD
Base 55.8(21.3) 51.2(16.2) (cid:5)2.9(4.5) 0.53(0.21) 0.32(0.13) (cid:5)0.18(0.14) 37.4(16) 26.7(13.8) 11.1(10.4)
15wk 56.1(19) 51.5(16.7) (cid:5)3.6(5.2) 0.57(0.2) 0.33(0.12) (cid:5)0.24(0.11) 34.3(17.2) 22.4(12.2) (cid:5)9.9(6.9)
28wk 54(17.3) 50.9(15.8) (cid:5)3.1(5.7) 0.58(0.19) 0.34(0.13) (cid:5)0.25(0.11) 32.8(10.6) 24.1(15.6) (cid:5)9(11)
Calcium(cid:6)vitaminD
Base 52.5(17.8) 55(18.2) (cid:5)1.29(4.5) 0.47(0.17) 0.32(0.16) (cid:5)0.17(0.13) 33.5(13) 22(10.6) (cid:5)11.5(9.5)
15wk 48.7(15.1) 47.2(15.2) (cid:5)2.6(7.2) 0.44(0.21) 0.27(0.11) (cid:5)0.18(0.13) 23.7(10.3) 18(8) (cid:5)5.8(6.4)
28wk 50.1(16) 45.9(14.3) 4.2(7.8) 0.45(0.17) 0.27(0.12) (cid:5)0.18(0.11) 24(11.6) 19.1(9.5) (cid:5)5(9.6)
Pvalues .686,b.002c .802,b(cid:1).001c .994,b.198c .437,b(cid:1).001c .225,b.003c .045,b.022c .075,b.036c .038,b.412c .725,b.266c
ciuriaineachgroup.Noadverseeventswerebelievedtobe ThedeclineinPTHunderhigh-calcium/high-25(OH)D
relatedtosupplementationotherthanhypercalciuria. conditionsmayrepresentapharmacologiceffect.Saiet
al(14)notedthatserumPTHdeclinescontinuouslyup
to 150 nmol/L. They propose that this decline may be
Discussion the result of pharmacologic effects of higher serum
25(OH)D or calcitriol on the vitamin D response ele-
This study provides insight into the response to dietary
mentinthePTHgene(14).Inconcertwithearlierstud-
supplementation with calcium and/or vitamin D. Before
ies, we found that serum calcitriol concentration rises
group assignment, a calcium load resulted in significant
with increasing doses of vitamin D supplementation
declines in PTH and bone turnover markers (CTX and
(see Supplemental Figure 2) (16).
P1NP)andanincreaseinurinarycalciumexcretion.The
Themeanbaselinedietarycalciumintakeinthecurrent
increaseinurinarycalciumexcretionpresumablyreflects
study was over 900 mg/d, and baseline serum 25(OH)D
thecalciumloadthatisnotused.Theseresponsesarelikely
was above 45 nmol/L, yet calcium supplementation did
seenaftereachingestionofacalciumsupplement(orcal-
reduceboneturnoverdespitesomestudiesthatwouldnot
cium-rich meal) and result in a postprandial decrease in
havepredictedthis(17,18).Becausethiswasnotadose-
PTH and bone resorption. After long-term dietary sup-
responsestudy,wecanonlyconcludethat1200mg/dof
plementation, a decline in fasting PTH is observed with
calcium supplements is more effective in reducing bone
vitaminDsupplementation,likelyasaresultofgenomic
turnoverthananunsupplementedintakeof900mg/d.The
effectsofcalcitriolontheparathyroid(14).Althoughcal-
calciumintakeinthecurrentstudywasattheUL(2000
ciumsupplementationappropriatelysuppressescalcitriol
mg/d)recommendedbytheIOM.TheULvaluewasbased
levels with high vitamin D intake (in the absence of cal-
cium supplementation), calcitriol levels do not decline onanincreasedriskofkidneystonesobservedinthecal-
frombaselineevenwhenacalciumloadsuppressesPTH. ciumsupplementationarmoftheWomen’sHealthInitia-
CalciumloadingismoreeffectiveinsuppressingPTHin tive(19).
thepresenceofvitaminDsupplementation. Inourpreviousstudy,boneturnovermarkersshowed
These findings are consistent with our previous study atrendtoincreaseinthehighvitaminDgroup(3).Inthe
thatwasnotage-,race-,orgender-specificandfoundthat current, more homogeneous study, an increase in bone
calciumsupplementationreducedboneturnovermarkers turnoverwasnotobservedinthehighvitaminDgroup.
butvitaminDsupplementationdidnot(7).Thisfindingis Thus,withintakesofvitaminDatthecurrentUL(4000
consistent with a recent food fortification study with a IU/d), we found no evidence for adverse effects on bone
similardesignandotherstudiesaswell(15). health in terms of increased bone turnover. The risk of
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
E1708 Aloiaetal CalciumandVitaminDSupplementation JClinEndocrinolMetab,November2013,98(11):E1702–E1709
Table 3. AdverseEventsbyRandomizationGroups
NumberofSubjectsWith>1Event
VitaminD Calcium Calcium(cid:3)Vitamin Placebo
SystemOrganClass(MedDRA) Group Group DGroup Group
Cardiacdisorders 0 1 3 0
Congenital,familial,andgeneticdisorders 0 0 0 0
Gastrointestinaldisorders 7 3 6 4
Generaldisordersandadministrationsiteconditions 0 0 0 1
Immunesystemdisorders 0 0 0 0
Infectionsandinfestations 4 2 5 4
Injury,poisoning,andproceduralcomplications 0 0 0 0
Investigations 0 0 0 0
Metabolismandnutritiondisorders 2 1 1 0
Musculoskeletalandconnectivetissuedisorders 4 5 6 3
Neoplasms:benign,malignant,andunspecified 0 0 0 0
(includingcystsandpolyps)
Nervoussystemdisorder 3 1 5 2
Psychiatricdisorders 0 0 0 0
Respiratory,thoracic,andmediastinaldisorders 1 1
Skinandsctissuedisorders 0 0 1 0
Surgicalandmedicalprocedures 0 0 0 0
Vasculardisorders 0 0 0 0
Total 20 14 26 14
increased bone turnover at the UL proposed by The En- that increased calcium supplementation reduced bone
docrineSociety(10000IU/d)isunknown. turnover,whereasincreasingserum25(OH)D(above50
We speculate that increasing calcium intake after the nmol/L)didnot.
calcitriol-dependentprocessissaturatedwillresultintran- Ourstudysupportsthebenefitofhighcalciumintake
scellular transport and a decline in postabsorptive PTH in reducing bone turnover in postmenopausal white
levels.ThedeclineinPTHafterthecalciumloadatbase- women.Theplacebogrouphadameandailycalciumin-
lineinourstudywasnotable.Theeffectofincreasedcal- takeof946mg.Boneturnoverwassignificantlyreduced
cium intake can best be detected in the postabsorptive bytheadditionof1200mg/dofcalciumsupplementsand
rather than the fasting state. The intermittent effect of furtherreducedbyacalciumload.Currentrecommenda-
calciumintakecanbereadilydetectedontheboneturn- tions for nutritional intake of calcium heavily relied on
overmarkers,indicatingasustainedeffectonboneturn- calcium balance studies (1). It is unknown whether this
over.Incontrast,vitaminDmayhaveagenomiceffecton effect would be sustained or whether it only reflects the
PTH secretion but at high levels may act directly to in- remodeling transient, although it has been sustained in
creaseboneremodeling,therebycounteractinganybene- somestudies(21–23).Moreover,itisunknownwhether
ficialinfluenceofPTHsecretiononboneturnover(5).A this is a pharmacologic effect and what the long-term
recent study found that standard vitamin D therapy de- safetyofveryhighcalciumintakemaybe(24).Ourcom-
creasedboneturnovertoagreaterextentthanveryhigh binedcalcium/vitaminDgrouphadmoreinstancesofhy-
doses(theequivalentof6500IU/d)(15). percalciuria. Hypercalciuria has been observed in other
There are several limitations of this study. A 24-hour studies as well (5, 13, 16). Studies using a less sensitive
measurement of PTH would have been preferable as definitionofhypercalciuria(ie,0.37Ca/Cr)maynothave
wouldalargersamplesize.Therehasbeenagreatdealof noteditspresence(25).
discussion in recent years about the most accurate assay
for serum 25(OH)D (20). However, our laboratory was
certified by the Vitamin D External Quality Assessment Acknowledgments
Scheme when these analyses were performed and was
WethankJaneGreensherforherexpertiseastheNurseCoor-
within the all-laboratory trimmed mean (ALTM). Fur-
dinator,MartinFeuermanandSamiranGhoshforcontributing
thermore,thisstudywasperformedinsubjectswhohad
tothedataandstatisticalanalyses,andLynnMaierforprepa-
baselineserum25(OH)Dlevelsactuallyabovetheserum
rationofthemanuscript.
25(OH)D-linked RDA recommendations of the IOM.
Nonetheless, the conditions of this study are similar to Addressallcorrespondenceandrequestsforreprintsto:John
advicethatmaybegiventowomencurrently,anditisclear F.Aloia,MD,WinthropUniversityHospital,222StationPlaza
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
doi:10.1210/jc.2013-2121 jcem.endojournals.org E1709
North, Suite 510, Mineola, New York 11501. E-mail: 11. MillenAE,MidthuneD,ThompsonFE,KipnisV,SubarAF.The
jaloia@winthrop.org. NationalCancerInstitutediethistoryquestionnaire:validationof
ThisworkwassupportedbyMerckandtheEmpireClinical pyramidfoodservings.AmJEpidemiol.2006;163:279–288.
ResearchInvestigatorProgram. 12. Little R, Rubin D. Statistical Analysis With Missing Data. New
DisclosureSummary:Theauthorshavenothingtodisclose. York,NY:Wiley;2002.
13. CohenJ.StatisticalPowerAnalysisfortheBehavioralSciences.2nd
ed.Hillsdale,NJ:LawrenceErlbaumAssociates;1988.
14. SaiAJ,WaltersRW,FangX,GallagherJC.Relationshipbetween
References vitaminD,parathyroidhormone,andbonehealth.JClinEndocri-
nolMetab.2011;96:E436–E446.
1. InstituteofMedicine.DietaryReferenceIntakesforCalciumand 15. Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B,
VitaminD,WA,DC:TheNationalAcademiesPress.2011;XXX. JordeR.Theeffectofhigh-dosevitaminDonbonemineraldensity
2. AloiaJF.The2011reportondietaryreferenceintakeforvitaminD: andboneturnovermarkersinpostmenopausalwomenwithlow
wheredowegofromhere?JClinEndocrinolMetab.2011;96:2987– bonemass–arandomizedcontrolled1-yeartrial.OsteoporosInt.
2996. 2012;23:201–211.
3. RossAC,MansonJE,AbramsSA,etal.The2011ReportonDietary 16. AloiaJF,TalwarSA,PollackS,YehJ.Arandomizedcontrolledtrial
ReferenceIntakesforCalciumandVitaminDfromtheInstituteof ofvitaminD supplementationinAfricanAmericanwomen.Arch
3
Medicine:whatcliniciansneedtoknow.JClinEndocrinolMetab. InternMed.2005;165:1618–1623.
2011;96:53–58. 17. SteingrimsdottirL,GunnarssonO,IndridasonOS,FranzsonL,Sig-
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, urdssonG.Relationshipbetweenserumparathyroidhormonelev-
treatment,andpreventionofvitaminDdeficiency:anEndocrine els,vitaminDsufficiency,andcalciumintake.JAMA.2005;294:
SocietyClinicalPracticeGuideline.JClinEndocrinolMetab.2011; 2336–2341.
96:1911–1930. 18. GanjiV,ZhangX,TangprichaV.Serum25-hydroxyvitaminDcon-
5. RosenCJ,AbramsSA,AloiaJF,etal.IOMcommitteemembers centrationsandprevalenceestimatesofhypovitaminosisDinthe
respondtoEndocrineSocietyvitaminDguideline.JClinEndocrinol
U.S.populationbasedonassay-adjusteddata.JNutr.2012;142:
Metab.2012;97:1146–1152.
498–507.
6. ChungM,BalkEM,BrendelM,etal.VitaminDandCalcium:A
19. Wallace RB, Wactawski-Wende J, O’Sullivan MJ, et al. Urinary
SystematicReviewofHealthOutcomes.EvidenceReportNo.183.
tractstoneoccurrenceintheWomen’sHealthInitiative(WHI)ran-
(PreparedbytheTuftsEvidence-basedPracticeCenterunderCon-
domizedclinicaltrialofcalciumandvitaminDsupplements.AmJ
tractNo.HHSA290-2007-10055-I.)AHRQPublicationNo.09-
ClinNutr.2011;94:270–277.
E015.Rockville,MD:AgencyforHealthcareResearchandQuality;
20. SnellmanG,MelhusH,GedeborgR,etal.2010.Determiningvita-
2009.
minDstatus:acomparisonbetweencommerciallyavailableassays.
7. AloiaJ,BojadzievskiT,YusupovE,etal.Therelativeinfluenceof
PloSOne.2010;5:e11555.
calciumintakeandvitaminDstatusonserumparathyroidhormone
21. AloiaJF,Arunabh-TalwarS,PollackS,YehJK.Theremodeling
andboneturnoverbiomarkersinadouble-blind,placebo-controlled
transientandthecalciumeconomy.OsteoporosInt.2008;19:1001–
parallel group, longitudinal factorial design. J Clin Endocrinol
1009.
Metab.2010;95:3216–3224.
22. HeaneyRP,ReckerRR,SavillePD.Calciumbalanceandcalcium
8. OrumO,HansenM,JensenCH,etal.ProcollagentypeIN-terminal
propeptide(PINP)asanindicatoroftypeIcollagenmetabolism: requirements in middle-aged women. Am J Clin Nutr. 1977;30:
ELISAdevelopment,referenceinterval,andhypovitaminosisDin- 1603–1611.
ducedhyperparathyroidism.Bone.1996;19:157–163. 23. Heaney RP. The bone-remodeling transient: implications for the
9. RosenHN,MosesAC,GarberJ,etal.SerumCTX:anewmarker interpretationofclinicalstudiesofbonemasschange.JBoneMiner
ofboneresorptionthatshowstreatmenteffectmoreoftenthanother Res.1994;9:1515–1523.
markersbecauseoflowcoefficientofvariabilityandlargechanges 24. BollandMJ,GreyA,GambleGD,ReidIR.CalciumandvitaminD
withbisphosphonatetherapy.CalcifTissueInt.2000;66:100–103. supplements and health outcomes: a reanalysis of the Women’s
10. CarterGD,CarterCR,GunterE,etal.MeasurementofvitaminD Health Initiative (WHI) limited-access data set. Am J Clin Nutr.
metabolites:aninternationalperspectiveonmethodologyandclin- 2011;94:1144–1149.
icalinterpretation.JSteroidBiochemMolBiol.2004;89-90:467– 25. KimballSM,UrsellMR,O’ConnorP,ViethR.SafetyofvitaminD
3
471. inadultswithmultiplesclerosis.AmJClinNutr.2007;86:645–651.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 February 2015. at 22:10 For personal use only. No other uses without permission. . All rights reserved.
